Defining the Minimal Important Difference in International Prostate Symptom Score for Men with Lower Urinary Tract...

Area of Science:

• Urology
• Clinical Trials
• Health Informatics

Background:

• Minimal important difference (MID) for the International Prostate Symptom Score (IPSS) is crucial for interpreting treatment outcomes in lower urinary tract symptoms (LUTS).
• Limited studies have established the IPSS MID, necessitating further investigation.

Purpose of the Study:

• To determine the IPSS MID in men experiencing LUTS.
• To utilize data from a randomized controlled trial (RCT) evaluating an app-based intervention for LUTS.

Main Methods:

• Secondary analysis of data from an RCT involving men with LUTS (benign prostatic hyperplasia, overactive bladder, or both).
• Participants used the Kranus Lutera app for 12 weeks and completed IPSS and Patient Global Impression of Change (PGIC) questionnaires.
• MID was calculated as the mean change in IPSS for men reporting "minimally improved" on the PGIC.

Main Results:

• The calculated IPSS MID was 5.26 points (95% CI 4.38-6.13).
• A higher MID was observed in men with severe baseline symptoms (8.23) compared to those with moderate symptoms (4.00).
• Generalizability may be limited due to data from a single RCT and small subgroup sample sizes.

Conclusions:

• The findings offer a valuable reference for clinicians assessing treatment outcomes for LUTS.
• The study highlights the need for further research in diverse populations to enhance generalizability and external validation of the IPSS MID.
• Results can inform future clinical trial designs for LUTS interventions.